1. Introduction {#sec0005}
===============

A variety of hematological diseases manifest in the bone marrow (BM), broadly characterized as BM failure (BMF), defined as an abnormality in erythroid, megakaryocytic, and monocyte cell lineages \[[@bib0005],[@bib0010]\]. In some cases, BMF can be caused by acute lymphoblastic leukemia (ALL), in which ALL cells engraft in BM, leading to hypoxia-inducible factor 1-alpha (HIF-1α) induction in the BM niche \[[@bib0015],[@bib0020]\]. This results in an expansion of hypoxic regions, which allows leukemic cells to infiltrate further, compromising normal hematopoietic cells \[[@bib0025]\]. Consequently, diagnosis and treatment of many hematological diseases stand to benefit from accurate characterization of BMF through assessment of *in vivo* oxygenation in the BM.

Current clinical methods to probe hypoxia, which is a lack of oxygen availability to cells, include (^18^F-FAZA)-PET imaging, BOLD-MRI, TOLD-MRI, and ^19^F-MRI. (^18^F-FAZA)-PET imaging has shown correlation with hypoxia immunostaining \[[@bib0030]\]; however, it requires injection of a radiotracer and suffers from inherently poor spatiotemporal resolution. BOLD-MRI is a label-free technique that suffers from quantitation issues, particularly at tissue-bone interfaces, due to susceptibility artifacts \[[@bib0035],[@bib0040]\]. Although not affected by such artifacts, TOLD-MRI's limited sensitivity has failed to provide substantial signal change in BM \[[@bib0045],[@bib0050]\]. ^19^F-MRI requires a perfluorocarbon exogenous reporter and additional imaging equipment that is not standard on an MRI scanner to generate dynamic pO~2~ maps \[[@bib0055],[@bib0060]\]. Preclinical methods to detect intracellular hypoxia include histological techniques (e.g., pimonidazole immunohistochemistry) and multiphoton intravital microscopy to probe carbonic anhydrase IX, a direct HIF-1α target \[[@bib0065],[@bib0070]\]. However, these techniques require an exogenous agent and are generally limited to sampling a single time-point \[[@bib0075]\]. To date, there is no established method for *in vivo*, label-free, noninvasive, quantitative imaging of oxygenation in BM.

Photoacoustic (PA) imaging is a noninvasive, label-free, *in vivo* imaging technique with high spatiotemporal resolution that provides optical contrast at significantly greater depths than purely optical techniques \[[@bib0080],[@bib0085]\]. Intravascular oxygen saturation (SO~2~) can be estimated through PA-based assessment of oxy- and deoxyhemoglobin (HbO~2~ and HHb, respectively) \[[@bib0090]\]. Although SO~2~ is not a direct measure of intracellular hypoxia, it has been shown to be correlated with pimonidazole-assessed hypoxia and pO~2~ levels proximal to capillaries \[[@bib0095],[@bib0100]\]. Therefore, we hypothesize that SO~2~ can serve as a noninvasive and label-free biomarker for leukemic disease progression and treatment response. This work demonstrates an optimized longitudinal PA imaging technique to probe the oxygenation status of the femoral BM. Results from a preclinical pilot study show that temporal changes in intrafemoral SO~2~ correlate with ALL disease progression.

2. Materials and methods {#sec0010}
========================

2.1. Mouse model {#sec0015}
----------------

All animal work was performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee. A transgenic murine leukemic BM cell (LBC) line was generated from murine Ai14/CD19-Cre BM B-cells that express TdTomato \[[@bib0065]\]. These cells were retrovirally transduced with the p190/Bcr-Abl oncogene and grown in cell culture for transduction with the Luciferase retrovirus \[[@bib0065]\]. 2 × 10^5^ LBCs were then suspended in PBS and inoculated intravenously into six- to eight-week-old B6-albino mice (Jackson Laboratory, Bar Harbor, ME). Engraftment was confirmed with bioluminescence imaging (BLI) at least 2 days post-injection ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1(A) Setup for PA imaging in MSOT inVision 256-TF. Mice are positioned as shown in orange dashed box, then placed in the scanner for imaging. Scan range is set to include the extent of both femurs (red volume; middle imaging frame indicated by green outline). Wavelengths were selected based on the HbO~2~ and HHb extinction spectra, as shown. Volume stack of PA images with corresponding noise images at (B),(D) 715 nm and (C),(E) 880 nm. Unmixed axial images with (F) HbO~2~ and HHb overlaid 800-nm image and (G) SO~2~ image. (H) SNR-masked SO~2~ image overlaid 800-nm image. Matched BLI at (I) day 4 and (J) day 11, showing increase in cell engraftment in femurs as disease progresses. Timeline at the bottom shows imaging time-points, with PA imaging indicated by blue circles and BLI indicated by green diamonds.Fig. 1

2.2. Imaging acquisition {#sec0020}
------------------------

All PA imaging was performed on the MSOT inVision 256-TF imaging system (iThera Medical, Munich, DEU), which has a 256-element, 270°-arc acoustic-receiver array with 5 laser-fiber-bundle pairs for PA signal generation. Images are acquired axially ([Fig. 1](#fig0005){ref-type="fig"}B--C), and the mouse is translated in the z-axis to obtain volumetric data. The wavelengths used in this study included 715, 730, 760, 800, 850, and 880 nm; at least 10 frame-averages were used for all acquisitions. Water temperature was maintained at 34 °C; mice were anesthetized with 1.2% isoflurane delivered via 100% oxygen at a flow rate of 0.8 L/min. Fur was removed with Nair prior to imaging, and a thin layer of ultrasound gel was applied to improve acoustic coupling.

Measures were taken to ensure repeatability of animal setup between imaging sessions. For the first time-point, the mouse was positioned with its hind limbs in the ankle cuffs and extended as far as reasonable ([Fig. 1](#fig0005){ref-type="fig"}A). This position was recorded to place the mouse in the same location at subsequent time-points. Mice were imaged over a 25 mm volume with a 0.2 mm step size, resulting in a scan time around 12 min; the scan volume included the full extent of both femurs, with extra frames superior and inferior to ensure the entire femur was sampled.

After all PA data were acquired, images were reconstructed by iterative reconstruction using the ViewMSOT software package (v.3.8, iThera Medical). Images were then unmixed for HbO~2~ and HHb using linear regression, and voxel-wise SO~2~ was calculated as the ratio of HbO~2~ to total hemoglobin \[[@bib0105]\]. Unless otherwise stated, reported SO~2~ values are defined as the average within a region of interest (ROI) encompassing the noted anatomy (i.e., intra-ROI mean).

2.3. CT/PA co-registration {#sec0025}
--------------------------

To verify that observed PA signals originated in the femoral BM, control mice were imaged on both the MSOT and the AlbiraSi X-ray CT (Bruker, Billerica, MA) imaging systems, verifying matched animal positioning with anatomical fiducials. 3D PA image data were then manually co-registered with 3D X-ray CT image data to determine whether the hemoglobin signal visible in PA images co-located with the BM cavity. Additionally, a noise threshold was applied to PA images to verify that only pixels with signal-to-noise ratio (SNR) \>6 dB were included in analysis \[[@bib0110]\].

2.4. System characterization {#sec0030}
----------------------------

To determine the optimal imaging parameters, it was necessary to balance scan time with SO~2~ estimation precision. Scan time increases linearly with wavelength number and frame-averaging; precision tends to maintain a nonlinear relationship with these parameters. Imaging-wavelength combinations (table, [Fig. 3](#fig0015){ref-type="fig"}) were assessed with 10-, 15-, and 20-frame averages in a wild-type ("control") mouse. Optimization was then determined based on the minimum of a cost function:$$\text{CF} = \sigma \times \text{nAvg}^{2}\text{,}$$where σ is the standard deviation in femoral-artery SO~2~ (S~a~O~2~) estimates (to assess measurement precision) and nAvg is the number of employed frame-averages (weighted more heavily to minimize scan time for noticeably frail leukemic mice). To obtain σ, four axial locations were imaged using parameters detailed in 2.2. S~a~O~2~ was obtained from an ROI encompassing the femoral artery; σ was then calculated as the standard deviation of S~a~O~2~ across the axial locations. The femoral artery was selected for this analysis because it is a known value (i.e., the mouse is breathing 100% O~2~, so we expect S~a~O~2~ near 100%) and is a clear anatomical marker in PA images.

Based on this optimization, three controls were imaged over five time-points (timeline, [Fig. 1](#fig0005){ref-type="fig"}) with six wavelengths and 15-frame averaging. Femoral-BM SO~2~ (S~f~O~2~) was obtained from ROIs placed over femoral- BM signals in 800-nm axial PA images. S~f~O~2~ for each mouse was assessed over the length of the femur ("femoral extent") for all five time-points; intra-ROI standard deviation was also calculated to ensure that ROI placement was correct. Then, to compare S~f~O~2~ across all controls, the intra-cohort mean and standard deviation ($\overline{\text{S}_{\text{f}}\text{O}_{2}}$ and $\sigma_{\text{S}_{\text{f}}\text{O}_{2}}$, respectively) were assessed over the femoral extent for all time-points.

2.5. Leukemia pilot study {#sec0035}
-------------------------

A pilot study was performed to compare temporal differences in $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ between control and leukemic mice through disease progression. Five mice were inoculated with LBCs, as described in [2.1](#sec0015){ref-type="sec"} ("leukemic"); three were not injected ("controls"). Each mouse was imaged at five time-points: pre-inoculation, and days 4, 7, 11, and 14 post-inoculation. Controls were imaged as described in [2.4](#sec0030){ref-type="sec"}; leukemic mice were imaged similarly with six wavelengths, but with 10-frame averaging to reduce imaging time for the frail leukemic cohort. BLI was performed at each post-inoculation time-point to track leukemic cell engraftment. $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ and $\sigma_{\text{S}_{\text{f}}\text{O}_{2}}$ were compared between cohorts at each time-point; statistical significance was determined by a two-tailed *t*-test (α = 0.05). Additionally, absolute changes in S~f~O~2~ were assessed relative to baseline for each mouse, and the intra-cohort mean of these changes ($\left| {\Delta\overline{\text{S}_{\text{f}}\text{O}_{2}}} \right|$; e.g., \| $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ ^Day11^ -- $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ ^Day0^\|) was assessed; statistical significance was determined by a two-way repeated measures ANOVA (α = 0.05). Day 14 results were excluded from analysis because leukemic mice had experienced paralysis and \>10% loss in body mass, which significantly confounded S~f~O~2~ measurements.

3. Results and discussion {#sec0040}
=========================

3.1. CT/PA co-registration {#sec0045}
--------------------------

Co-registered PA and CT images of a control mouse demonstrate colocalization of the femoral PA (i.e., hemoglobin) signal and the CT-delineated BM cavity ([Fig. 2](#fig0010){ref-type="fig"}C). The BM PA signal appears diffuse due to intra-cavity sound reverberation. Additionally, the applied SNR threshold helped to better delineate the femoral-BM PA signal ([Fig. 2](#fig0010){ref-type="fig"}D).Fig. 2(A) Axial PA image in a representative mouse showing 800-nm background (grayscale) with HbO~2~ (red) and HHb (blue) unmixed overlay with signal from femoral BM (indicated by teal circles); (B) matched X-ray CT to show anatomy. (C) Overlay of X-ray CT on PA image shows that the hemoglobin signal seen in the PA image co-locates with the BM cavity seen on X-ray CT, indicating that the signal originated in the BM. Femoral arteries are indicated by red circles. (D) SNR-masked SO~2~ image overlaid on 800-nm PA image demonstrates that sufficient SNR is achieved in the BM cavity to reliably estimate femoral SO~2~.Fig. 2

3.2. System characterization {#sec0050}
----------------------------

Optimized wavelength/averaging combinations were determined based on minima of the cost function (Eq. [(1)](#eq0005){ref-type="disp-formula"}), which selected 6-wavelength unmixing and either 10- or 15-frame averaging (red circles, [Fig. 3](#fig0015){ref-type="fig"}A). Using these parameters, control mice were imaged over five time-points to assess temporal variability of $\overline{\text{S}_{\text{f}}\text{O}_{2}}$. The average of $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ estimates across the femoral extent and all time-points was 46.1 ± 1.0%. Spatial dependence in S~f~O~2~ is evident across the femoral extent: S~f~O~2~ tends to increase towards the distal end ([Fig. 3](#fig0015){ref-type="fig"}B,C). This could be attributed to differences in depths of femoral-BM PA signals as there is more soft tissue surrounding the proximal end than the distal end. Varying depths could affect the accuracy of HbO~2~ and HHb unmixing (due to wavelength-dependent optical attenuation \[[@bib0090]\]) and therefore change the calculated S~f~O~2~. However, day-to-day S~f~O~2~ estimates in each frame showed less than 2.4% S~f~O~2~ variation in each subject, implying that this effect is temporally stable and thus allows for longitudinal assessment of other factors, such as disease progression.Fig. 3(A) Plot of cost function for all tested acquisition parameters. Wavelength combinations are shown in the table on the top right. PA-based (B) S~f~O~2~ for a representative control mouse and (C) $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ for control cohort. The average $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ across the femoral extent for all time-points are summarized in the table on the bottom right.Fig. 3

3.3. Leukemia pilot study {#sec0055}
-------------------------

At day 0 in the leukemic cohort, $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ averaged over the femoral extent was 45.8%; at day 11, this reduced to 36.8%. Additionally, leukemic $\sigma_{\text{S}_{\text{f}}\text{O}_{2}}$ averaged over the femoral extent increased from 5.2% at day 0 to 10.2% at day 11 (shaded regions, [Fig. 4](#fig0020){ref-type="fig"}). Neither of these changes was statistically significant. As BM hypoxia increases, the expectation would be for S~f~O~2~ to decrease; however, as demonstrated by the high $\sigma_{\text{S}_{\text{f}}\text{O}_{2}}$ at day 11, some leukemic mice experienced increased S~f~O~2~ with disease progression relative to baseline, while others experienced decreased S~f~O~2~. This indicates that although hypoxia and S~f~O~2~ are correlated, they are not directly related. S~f~O~2~ assesses vascular oxygenation, whereas hypoxia exists further downstream in the extravascular compartment and can be caused by a variety of biological effects (i.e., abnormalities in vasculature or sufficient diffusion distance \[[@bib0115]\]), which cannot be discerned from S~f~O~2~ assessment alone.Fig. 4PA-based femoral SO~2~ for control (blue) and leukemic (red) mice at (A) day 0, (B) day 4, (C) day 7, and (D) day 11. Each line shows $\overline{\text{S}_{\text{f}}\text{O}_{2}}$ for the cohort, and shaded regions indicate $\sigma_{\text{S}_{\text{f}}\text{O}_{2}}$ for the cohort.Fig. 4

[Fig. 5](#fig0025){ref-type="fig"} shows plots of $\left| {\Delta\overline{\text{S}_{\text{f}}\text{O}_{2}}} \right|$ across the femoral extent. Statistical significance was assessed separately in three regions: the proximal end, the femoral body, and the distal end. There was a statistically significant difference in $\left| {\Delta\overline{\text{S}_{\text{f}}\text{O}_{2}}} \right|$ between the leukemic and control cohorts in the femoral body region (asterisks, [Fig. 5](#fig0025){ref-type="fig"}). Therefore, it may be necessary to measure subject-specific temporal changes in S~f~O~2~ to be sensitive to changes in leukemic disease progression.Fig. 5$\left| {\Delta\overline{\text{S}_{\text{f}}\text{O}_{2}}} \right|$ for (A) day 4 -- day 0, (B) day 7 -- day 0, and (C) day 11 -- day 0. There is a statistically significant difference between controls (blue) and leukemic (red) mice in the middle region of the femur, as indicated by \* (Repeated Measures Two-Way ANOVA; α = 0.05), between leukemic and control cohorts.Fig. 5

In future studies, contrast may be further improved by varying oxygen inhalation conditions (e.g., 100% and 21% O~2~), a method that has been demonstrated in other disease models \[[@bib0120]\]. Additionally, S~f~O~2~ measurements at the final time-point could be correlated with hypoxia through immunohistochemical analysis, which is established for this disease model \[[@bib0065]\]. These studies will help further discern the relationship between $\left| {\Delta\overline{\text{S}_{\text{f}}\text{O}_{2}}} \right|$ and leukemic disease progression. PA-based S~f~O~2~ assessment could, in turn, be used as a preclinical assay to assess the efficacy of novel ALL treatments currently under investigation \[[@bib0125]\]. Furthermore, this assay could be applied to a variety of BMF applications, particularly aplastic anemia, in which there is a reduction in hematopoietic production \[[@bib0010]\]. Although clinical PA-based measurements in BM may be difficult, some sites (e.g., appendages) could be imaged with an arc-array, which offers an increased receive angle for improved sensitivity \[[@bib0130]\]. This would be particularly applicable to pediatric patients, whose bones are thinner and more readily permit one-way transmission of PA-generated US signal out of the BM cavity \[[@bib0135],[@bib0140]\].

4. Conclusions {#sec0060}
==============

This work presents an optimized *in vivo*, noninvasive, label-free PA imaging technique for S~f~O~2~ estimation, demonstrating a repeated-measure variability of less than 2.4% in a control cohort. This technique was applied to a pilot cohort of leukemic mice, and temporal changes in S~f~O~2~ demonstrated a statistically significant correlation with leukemic disease progression. PA-based S~f~O~2~ imaging is able to reliably assess changes in BM oxygenation status, an emerging imaging biomarker that has potential to provide valuable insight into many hematological diseases that manifest as BMF.
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